Emergent BioSolutions Inc. and Substipharm Biologics have entered into a $34.5 million partnership that will see the Canton, Massachusetts facility manufacture the Japanese Encephalitis (JE) vaccine IMOJEV® and grant Emergent exclusive U.S. government distribution rights once the product receives FDA approval.
The Canton plant, a BSL‑2, multi‑product facility that received a “No Action Indicated” classification from the FDA after a February 2026 inspection, has already produced IMOJEV drug substance for international markets. A master manufacturing services agreement will prepare the vaccine for U.S. regulatory submission, positioning Emergent to scale production quickly once approval is obtained.
In the United States, the only JE vaccine currently available is IXIARO®. IMOJEV is licensed and used in several Asian countries, and the partnership could bring this product to U.S. travelers and other at‑risk populations once FDA approval is secured, filling a notable unmet need.
Strategically, the deal expands Emergent’s biodefense and vaccine portfolio and creates a new revenue stream tied to a government‑backed product. It also aligns with the company’s multi‑year turnaround strategy by leveraging existing manufacturing assets, onshoring production, and securing a government contract that can help stabilize cash flow.
Financially, Emergent reported Q4 2025 revenue of $148.7 million and a net loss of $54.6 million, while full‑year 2025 revenue reached $742.9 million with a net income of $52.6 million. In comparison, Q4 2024 revenue was $194.7 million with a net loss of $31.3 million, and full‑year 2024 revenue was $1.04 billion. The company is scheduled to report Q1 2026 earnings on April 30, and the new partnership is expected to support its ongoing financial improvement.
CEO Joe Papa emphasized that the partnership is a “critical step in our efforts to onshore production of critical medicines and leverage our specialized capabilities to support” the company’s growth objectives, underscoring confidence in execution and future expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.